Cormedix Inc. splits its revenue into 5 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Defen Cath at $66.1 million, 65% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
462
|
102
|
127
|
129
|
102
|
40
|
39
|
31
|
11
|
| Defen Cath |
—
|
66
+66.4%
share 64.9%
|
98
+149.5%
share 76.5%
|
91
+192.3%
share 70.9%
|
89
+674.8%
share 87.4%
|
40
share 100.0%
|
39
share 100.0%
|
31
share 100.0%
|
11
share 100.0%
|
| Product |
—
|
—
|
—
|
—
|
—
|
40
share 100.0%
|
39
share 100.0%
|
31
share 100.0%
|
11
share 100.0%
|
| Melinta Portfolio |
—
|
28
share 27.7%
|
24
share 19.2%
|
33
share 25.5%
|
13
share 12.6%
|
—
|
—
|
—
|
—
|
| Contract Revenue |
—
|
5
share 4.9%
|
6
share 4.3%
|
5
share 3.6%
|
3
share 2.7%
|
—
|
—
|
—
|
—
|
| Grant Income |
—
|
3
share 2.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Parsippany, NJ
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1410098
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.